

1-Day Training

Bioequivalence Study

Design, Analysis, Safety & Efficacy

**Saturday,
October 5, 2024
Lahore**

**Saturday,
October 12, 2024
Karachi**

In this one-day training workshop participants will gain comprehensive understanding of designing robust bioequivalence studies, including regulatory requirements and statistical methodologies.

Training Outline

- Definition of Bioequivalence
- Why do we need Bioequivalence studies?
- The Importance of Bioequivalence in Generic Drugs: Ensuring Safety and Efficacy
- Sulfanilamide disaster (1937)
- Thalidomide in the late 1950s and early 1960s
- What is a Generic Drug?
- Bioavailability (BA) & Bioequivalence
- Path of Drug: From Tablet to Blood
- Pathway of Drug Elimination
- General methods of establishing BE of Solid Oral Dosage Forms
- Test methods for assessing bioequivalence
- Conditions where bioequivalence studies are not necessary
- BA studies protocol & Study design
- cMax & Curve (AUC)
- Sample & Record Maintenance

**Rs.
20,000/-**
Investment

Who Should Attend

- Professionals from Pharmaceutical Organizations, Laboratories, Hospitals
- Pharmacy Graduates

Registration Link & Details

<http://fidnos.com/trainings>

Or training@fidnos.com

WhatsApp: 0331-1160601

Website: <https://fidnos.com>

Trainer Profile

Dr. M. Asghar Khan is a distinguished Senior Scientific Officer at the Bioequivalence and Drug Testing Lab, National University of Medical Sciences (NUMS), Rawalpindi, Pakistan & has over 20 years of experience in the pharmaceutical industry, having held senior positions in various pharmaceutical companies. With a Ph.D. in Biochemistry and advanced training from institutions such as Johns Hopkins University and the University of Toronto, Dr. Khan possesses extensive expertise in R&D and quality control. He is a recognized keynote speaker at international conferences and has a robust track record in research on drug efficacy and genetic polymorphism.

His advanced coursework in clinical trials and data management further highlights his dedication to advancing pharmaceutical sciences and education.

FidNos
Corporation